Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
about
Natalizumab in Multiple Sclerosis: Long-Term Management.Quantification of γδ T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatment.Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.Transcriptional signature of human pro-inflammatory TH17 cells identifies reduced IL10 gene expression in multiple sclerosis.Dysregulated MicroRNA Involvement in Multiple Sclerosis by Induction of T Helper 17 Cell Differentiation.
P2860
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
@en
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
@nl
type
label
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
@en
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
@nl
prefLabel
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
@en
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
@nl
P2093
P2860
P356
P1476
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
@en
P2093
Alexander Schwarz
Brigitte Wildemann
Katharina Schneider
Mirjam Korporal-Kuhnke
Simon Faller
Sven Jarius
P2860
P304
P356
10.1177/1352458516640609
P577
2016-07-11T00:00:00Z